RISE Adult Medication Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for RISE Adult Medication Study (NCT01779362), a randomized phase 3 study. The primary outcome is ß-cell Response Measured by Hyperglycemic Clamp.

2. Clinical Question

RISE asked whether improvements in ß-cell function after 12 months of active treatment would be maintained for 3 months after therapy was withdrawn. The clinical question concerns the durability of a physiological response after treatment ends, rather than only the response while participants are taking medication. The registry record lists a hyperglycemic-clamp measure of ß-cell response at Month 15 as the primary endpoint, with the primary analysis including participants who attended that visit.

Secondary aims addressed glucose tolerance after withdrawal and whether fasting biomarkers predicted ß-cell function, insulin sensitivity, glucose tolerance, or response to an intervention. These questions concern distinct outcomes and potential predictors. The registry record does not report their results, so the clinical question can be described, but the direction and precision of any observed treatment differences cannot be established from the record.

3. Trial Design

RISE Adult Medication Study was a Phase 3, randomized, quadruple-masked, parallel-group clinical trial. The registry record lists 267 participants and describes the study as a 4-arm, 3-center trial. The study enrolled adults with prediabetes or early type 2 diabetes, with eligible ages stated as 20-65. The record lists a start of 2013-04, primary completion in 2019-02, and a completed status.

The four regimens were not identical in how masking and treatment were implemented. The metformin-alone arm used blinded metformin titrated to the maximum tolerated dose, up to 2000 mg/day. The placebo arm was masked to metformin alone, with placebo titrated to a tablet count equivalent to the maximum metformin dose. The glargine regimen began with basal insulin for 3 months, titrated toward a morning fasting blood glucose of 80-90 mg/dl, then continued with open-label metformin for 9 months. The liraglutide regimen used liraglutide plus open-label metformin; liraglutide was titrated up to 1.8 mg/day, followed by metformin titrated up to 2000 mg/day.

The treatment plans therefore combine different drugs, sequences, and masking arrangements. The primary question focuses on persistence after medication withdrawal, while secondary outcomes address glucose tolerance and biomarkers. The registry record does not report the allocation ratio, details of how quadruple masking was implemented across all regimens, or a detailed statistical analysis plan. It also does not report an explanation of the planned sample size.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Primary analysis was on all participants who attended their M15 visit.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as ß-cell Response Measured by Hyperglycemic Clamp, measured over 3-months after medication washout (Month 15).

The primary endpoint is ß-cell response measured by hyperglycemic clamp, reported in nmol/L as a geometric mean with a 95% confidence interval. The assessment time is 3-months after medication washout (Month 15). The record describes the clamp measures as co-primary outcomes and states that the primary analysis included participants who attended the M15 visit.

A hyperglycemic clamp is a controlled physiological assessment that measures the insulin-secretory response to elevated glucose. In general, ß-cell response is relevant because ß-cells produce insulin, and their function is part of the biology underlying glucose regulation. Measuring response after washout is intended to address whether changes persist beyond active medication exposure. That is a different question from whether a drug changes glucose or insulin measures during treatment.

Geometric means summarize measurements on a multiplicative scale and can be useful when values are skewed. A 95% confidence interval conveys uncertainty around the estimated endpoint value; it is not a range that contains every participant's measurement. The registry record does not report the geometric mean estimates, confidence limits, or treatment comparisons. It also indicates multiple co-primary outcome categories or time points, so the endpoint is not reduced in the record to a single comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record describes a randomized, quadruple-masked, parallel-group study with four treatment arms. Statistical interpretation depends not only on randomization, but also on the outcome definition, analysis population, treatment contrast, and uncertainty around estimates. Several of these details are not reported in the registry record, so the methods can be explained only to the level of detail the record supplies.

What does randomization contribute?

In general, random allocation is intended to make treatment groups comparable at the start of a trial, including with respect to factors that are measured and factors that are not measured. This supports a causal interpretation of a treatment contrast when the analysis follows the trial design and when missingness, adherence, and other departures from the planned comparison are handled appropriately. Randomization does not guarantee that every group will be identical, and it does not remove the need to report baseline characteristics and the analysis population. The registry record does not report the allocation ratio or details of the randomization procedure.

How should the primary measure be read?

The endpoint is ß-cell response measured by hyperglycemic clamp, expressed as a geometric mean in nmol/L with a 95% confidence interval. In general, a geometric mean is appropriate for data that are naturally interpreted on a multiplicative scale or have a skewed distribution. It summarizes the central tendency after accounting for that scale; it does not describe the full spread of individual observations. A confidence interval communicates statistical uncertainty around an estimate under the assumptions of the analysis. It is not an interval for individual participant values and does not by itself identify whether a treatment contrast is statistically or clinically important.

The endpoint is assessed 3-months after medication washout (Month 15), which makes the timing central to interpretation. It concerns the state after treatment has been withdrawn, not the response while participants remain on treatment. The record calls the clamp measures co-primary outcomes. It does not give individual outcome definitions for each co-primary measure or their separate numerical estimates.

What can be inferred from the analysis population?

The primary analysis was on all participants who attended their M15 visit. In general, restricting an analysis to those with an observed visit can lead to a different interpretation from an analysis of all randomized participants, especially if attendance is related to treatment, health status, or the outcome. A complete-visit analysis does not automatically correct for missing data. Evaluating this issue requires information about attendance, reasons for missing visits, group-specific missingness, and any sensitivity analyses. Those details are not reported in the registry record.

The record does not report whether the primary analysis used an adjusted model, transformed measurements, covariate adjustment, or a particular method for estimating the geometric means and confidence intervals. It also does not report the method used to compare treatment arms. These details matter because the reported estimates and their uncertainty depend on the analysis specification.

Why does the four-arm structure matter?

With several treatment arms and co-primary outcomes, the inferential question may involve more than a single pairwise comparison. In general, testing multiple contrasts can increase the chance of at least one false-positive finding if each test is treated as independent evidence without an appropriate strategy. A prespecified multiplicity approach can control or otherwise address this concern. The registry record does not report a multiplicity strategy, a hierarchy among outcomes, or which comparisons were designated as primary. It is therefore not possible to determine how any set of treatment comparisons should be interpreted as a family of tests.

The four regimens also represent different treatment strategies: metformin alone, placebo, glargine followed by metformin, and liraglutide plus metformin. The contrasts are not necessarily interchangeable. A comparison of one active regimen with placebo addresses a different question from a comparison between two active regimens. Since no single primary pairwise comparison is reported, the intended principal contrast cannot be assumed.

How do planning illustrations differ from trial results?

Sample-size planning illustrations based on an observed effect are not observed treatment effects and are not a measure of the trial's achieved power. In general, such illustrations ask how many participants per arm would be needed under specified assumptions to detect a chosen fraction of an effect, using a selected significance level, allocation approach, and statistical approximation. The stated illustration assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustrations are described as based on the observed effect, not on the trial's original design. The registry record does not report numerical planning results in the registry record for this description, and those assumptions should not be mistaken for a trial protocol or sample-size justification.

These distinctions are important: the design information describes how the trial was organized; an endpoint estimate describes observed data; an inferential comparison estimates a treatment contrast; and a planning illustration describes a hypothetical future design under assumptions. The registry record provides the first category and an endpoint definition, but it does not report the primary outcome estimates or enough analysis details to evaluate the comparative inference.

10. Multiplicity, Missing Data and Analysis Populations

The registry record identifies co-primary clamp outcomes and indicates that the primary outcome has several categories or time points rather than a single reduced comparison. It does not report a hierarchy among the co-primary outcomes, a designated primary contrast, or a multiplicity adjustment. In general, multiplicity matters when investigators draw conclusions from several outcomes, time points, or treatment comparisons. Without an approach that accounts for the planned family of tests, the chance of a false-positive result across that family may be higher than for an isolated test. The record does not establish which outcomes or contrasts were included in such a family.

The primary analysis is described as including all participants who attended the M15 visit. This is an analysis-population statement, not a complete account of missing-data handling. The number of participants attending that visit, attendance by treatment arm, reasons for nonattendance, and the number of observed endpoint values are not reported in the registry record. No imputation method, model for missing outcomes, or sensitivity analysis is described. The impact of missing data on the estimates therefore cannot be assessed from this record.

The record also does not report whether the primary analysis was intention-to-treat, per-protocol, or another named approach. It states the analysis population in terms of M15 attendance, but gives no further definition of adherence or protocol deviations. These omissions limit assessment of how closely the analyzed participants represent everyone randomized and whether conclusions would be robust to different assumptions about missing outcomes.

Finally, the record does not report whether interim analyses were conducted or whether any statistical stopping rules were used. Those details are not reported in the registry record, and no assumptions about them can be made from the completed status alone.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: chest pain (3.0%), arthroplasty (1.5%), food poisoning (1.5%), infection (1.5%), earache (1.5%).

The registry record lists serious and other adverse events by treatment group. For metformin alone, 5 participants were affected by serious adverse events and 29 by other adverse events, among 65 at risk. For glargine followed by metformin, the corresponding counts were 2 and 28 among 67 at risk. For placebo, the counts were 3 and 23 among 67 at risk. For liraglutide plus metformin, the counts were 7 and 30 among 68 at risk. Deaths were recorded as 0 in each group.

These are group-level counts of participants affected, not comparative estimates. They do not by themselves show whether a difference between groups is compatible with chance or quantify the uncertainty around a safety contrast. The registry record does not report comparative statistical analyses or confidence intervals for these outcomes. The meaning of the category “other adverse events” is not further specified in the information available.

The listed serious-event terms include chest pain at 3.0%, and arthroplasty, food poisoning, infection, earache, and carpal tunnel each at 1.5%. The registry record does not state the denominator used for these percentages or provide a complete event-level breakdown. These terms should therefore be read as the reported serious-event terms, not as a complete account of all observed safety experiences. The counts and terms describe what is recorded; they do not establish that regimens have equivalent safety profiles.

12. What the Result Does, and Does Not, Mean

The registry record establishes the purpose and structure of RISE: a randomized study of medication regimens in adults with prediabetes or early type 2 diabetes, with a primary focus on ß-cell response after medication washout. It identifies the primary assessment at Month 15 and the analysis population as participants who attended that visit. It also reports adverse-event counts by group and a completed study status.

Those details do not establish the primary treatment effects. The record does not report geometric mean endpoint estimates, 95% confidence intervals, treatment contrasts, p-values, or results for the stated secondary outcomes. Accordingly, it is not possible to determine from the registry record whether the endpoint changed in any arm, whether changes differed between arms, or how precisely any differences were estimated. A completed trial designation is not a substitute for outcome results.

The trial's intended question is about persistence after treatment withdrawal. This is distinct from a question about glucose lowering during active treatment, and the timing of the endpoint is essential to interpreting the study's aim. However, the record's endpoint definition and hypothesis do not demonstrate that an effect persisted. That determination requires observed results and a clearly specified comparison.

Likewise, the reported safety counts do not show that the regimens are the same or different in safety. The counts are not accompanied by comparative estimates or uncertainty measures, and the registry record does not provide detailed event-level information. Zero deaths are recorded in each arm, but that observation alone cannot characterize all aspects of safety.

The appropriate reading is therefore limited: the record documents a trial designed to examine the durability of ß-cell response, describes its treatment strategies and endpoint, and provides selected adverse-event counts. It does not provide enough outcome or analysis information to support conclusions about the comparative effectiveness, durability, or overall safety of the regimens.

13. Why This Trial Matters Statistically

This trial is statistically notable for asking a durability question rather than limiting assessment to the period of active medication use. The endpoint timing—3-months after medication washout (Month 15)—defines an estimand focused on response after treatment withdrawal. That makes the relationship between treatment exposure, washout, visit attendance, and the endpoint especially important to interpretation.

The four-arm structure creates multiple possible comparisons. Metformin alone and placebo form one kind of contrast, while comparisons among the active regimens address different questions about treatment strategy. The regimens also differ in sequencing and masking, including open-label components. Without a reported primary contrast and multiplicity approach, it is difficult to know which comparison should anchor the main inference or how a collection of findings should be interpreted.

The stated analysis population also has statistical importance. The primary analysis includes participants who attended the M15 visit, while the registry record does not report attendance counts or missing-data methods. In a study focused on a post-withdrawal assessment, the pattern of missing visits could affect which participants contribute endpoint data. Evaluating that possibility requires information absent from the record.

The record's endpoint scale adds another interpretive consideration. Geometric means and confidence intervals can be appropriate for measurements analyzed on a multiplicative scale, but the scale does not remove the need for clearly reported contrasts and uncertainty. Since the actual estimates and comparisons are not reported, readers cannot assess the magnitude or precision of the primary findings.

These features make the registry entry useful for understanding the design questions that matter in a durability trial: the timing of measurement, the comparison strategy, the handling of multiple outcomes, and the relationship between attendance and analysis. They also make clear why design information alone cannot substitute for reported outcome estimates and analysis details.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the available registry record is that it does not report the primary outcome estimates or treatment comparisons. The endpoint is defined, but the geometric means and their 95% confidence intervals are not reported. Results for the secondary outcomes are also not reported in the registry record. This prevents assessment of the direction, magnitude, and precision of the trial's main findings.

The analysis description is limited to participants who attended the M15 visit. Attendance numbers, reasons for missing visits, group-specific missingness, and methods for addressing missing data are not reported. The registry record also does not identify whether the analysis was intention-to-treat, per-protocol, or another approach. These gaps restrict assessment of possible selection effects and the relation between the primary analysis and randomization.

The record does not report a single primary pairwise comparison, the multiplicity strategy for co-primary outcomes and multiple categories or time points, or whether interim analyses were conducted. It does not provide a detailed statistical analysis plan, the allocation ratio, or a sample-size justification. The sample-size illustrations described in the record are planning exercises based on the observed effect, not evidence about the original design rationale or the trial's achieved power.

Safety information is also limited to selected group counts and serious-event terms. Comparative analyses, uncertainty estimates, a detailed event-level account, and the denominator for the listed percentages are not reported in the registry record. The four regimens include differing treatment sequences and open-label components, while the record does not explain how masking was maintained across the study. These reporting limitations mean that the available entry supports description of the trial design, but not a full assessment of outcome validity or comparative safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: RISE Adult Medication Study — NCT01779362.
• Registry record last updated 2023-05-11; status last verified 2018-08.
• Results first posted 2023-05-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

RISE Adult Medication Study was a completed, randomized, quadruple-masked, parallel-group Phase 3 trial involving 267 adults with prediabetes or early type 2 diabetes. It compared metformin alone, placebo, glargine followed by metformin, and liraglutide plus metformin. The registry lists a start of 2013-04 and primary completion in 2019-02.

The primary endpoint was ß-cell response measured by hyperglycemic clamp at Month 15, 3-months after medication washout, reported as a geometric mean with a 95% confidence interval. The primary analysis included participants who attended the M15 visit. The record describes co-primary outcomes and secondary aims concerning glucose tolerance and biomarkers.

Group-specific serious and other adverse-event counts and zero deaths in each group are reported. However, primary and secondary outcome estimates, comparative treatment results, detailed missing-data methods, and a multiplicity strategy are not reported in the registry record. The available information describes the study and its aims but does not establish the comparative results.